Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome

• Authors: Levent Kebapcilar , Arif Yuksel , Giray Bozkaya , Cuneyt Taner , Ayse Kebapcilar , Oktay Bilgir , Ahmet Alacacioglu , Ismail Sari
• Languages of publication: EN

Abstracts

EN

To determine the effects of EE/CA (Ethinylestradiol/ Cyproterone Acetate) and EE/CA-metformin treatments on the asymmetric dimethylarginine (ADMA) levels in women with PCOS (Polycystic Ovary Syndrome). Among 43 patients diagnosed with PCOS, one study arm (n=22) was administered (35 µg EE, 2mg CA) and the other (n=21) was administered (35 µg EE, 2mg CA plus 1700mg metformin). Serum ADMA, lipid profile, androgens, insulin, and HOMA-IR (Homeostatic Model Assessment of Insulin Resistance ) values were assessed prior to treatment and after 3 months of therapy. A significant reduction in ADMA levels relative to pre-treatment in the EE/CA+metformin group (1.2±0.4 vs 0.95±0.4, p=0.016) compared to the EE/CA group (1.0±0.5 vs 1.03±0.4, p >0.05). Andogens, insulin and HOMA-IR levels decreased in both treatment groups. All lipid profiles significantly improved in-group EE/CA+metformin while no significant decrease was observed in TG and HDL-cholesterol levels in EE/CA group. Post-treatment levels of HDL-C levels correlated significantly with the reducing ADMA levels in the EE/CA+metformin group (P=0.005, r= 0.602). Adding metformin to EE/CA therapy in PCOS may beneficial endothelium effects associated with reduction of ADMA levels.

Keywords

EN

Ethinylestradiol; Cyproterone acetate; Metformin; ADMA; PCOS

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2009
• Volume: 4
• Issue: 4
• Pages: 423-427

Dates

published

1 - 12 - 2009

online

3 - 10 - 2009

Contributors

author

Levent Kebapcilar

• Department of Internal Medicine, (Endocrinologist), Bozyaka Training and Research Hospital, 35380, Izmir, Turkey

author

Arif Yuksel

• Department of Internal Medicine, Bozyaka Training and Research Hospital, 35380, Izmir, Turkey

author

Giray Bozkaya

• Department of Biochemistry, Bozyaka Training and Research Hospital, 35380, Izmir, Turkey

author

Cuneyt Taner

• Department of Obstetrics and Gynecology, Aegean Obstetrics and Gynecology Teaching Hospital, 35120, Izmir, Turkey

author

Ayse Kebapcilar

• Department of Obstetrics and Gynecology, Aegean Obstetrics and Gynecology Teaching Hospital, 35120, Izmir, Turkey

author

Oktay Bilgir

• Department of Internal Medicine, Bozyaka Training and Research Hospital, 35380, Izmir, Turkey

author

Ahmet Alacacioglu

• Department of Internal Medicine, Bozyaka Training and Research Hospital, 35380, Izmir, Turkey

author

Ismail Sari

• Department of Internal Medicine, Bozyaka Training and Research Hospital, 35380, Izmir, Turkey

References

• [1] Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60:1–17. http://dx.doi.org/10.1046/j.1365-2265.2003.01842.x[Crossref]
• [2] Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, Mittermayer F, Wolzt M, Krzyzanowska K, Randeva H, Schernthaner G, Lehnert H. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008; 93: 82–90. http://dx.doi.org/10.1210/jc.2007-0842[WoS][Crossref]
• [3] Charitidou C, Farmakiotis D, Zournatzi V, Pidonia I, Pegiou T, Karamanis N, Hatzistilianou M, Katsikis I, Panidis D. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis 2008; 196: 958–965. http://dx.doi.org/10.1016/j.atherosclerosis.2007.03.002[Crossref][WoS]
• [4] Ozgurtas T, Oktenli C, Dede M, Tapan S, Kenar L, Sanisoglu SY, Yesilova Z, Yenen MC, Erbil MK, Baser I. Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis 2008; 200: 336–344. http://dx.doi.org/10.1016/j.atherosclerosis.2007.12.054[WoS][Crossref]
• [5] Moran LJ, Hutchison SK, Meyer C, Zoungas S, Teede HJ. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. Clin Sci (Lond) 2008 13. [Epub ahead of print]. [WoS]
• [6] Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141–1146.
• [7] Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez-Bermejo E, Lasunción MA, Escobar-Morreale HF. Comparison of ethinylestradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 2453–2461. http://dx.doi.org/10.1210/jc.2007-0190[Crossref][WoS]
• [8] Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007; 24(1):CD005552. [WoS]
• [9] Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007; 30: 471–478. http://dx.doi.org/10.2337/dc06-0618[Crossref][WoS]
• [10] Wu J, Zhu Y, Jiang Y, Cao Y. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecol Endocrinol 2008; 24: 392–398. http://dx.doi.org/10.1080/09513590802217027[Crossref]
• [11] Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 2002;17: 1729–1737. http://dx.doi.org/10.1093/humrep/17.7.1729[Crossref]
• [12] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19–25.
• [13] Schulze F, Wesemann R, Scwedhelm E, Arakawa N, Sydow K, Albsmeier J, Ooke JP, Boger RH. Determination of asymmetric dimethylarginine (ADMA) sing a novel ELISA assay. Clin Chem Lab Med 2004; 42:1377–1383. http://dx.doi.org/10.1515/CCLM.2004.257[Crossref]
• [14] Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Munzel T. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005; 97: 1–7. http://dx.doi.org/10.1161/01.RES.0000181286.44222.61[Crossref]
• [15] Chikani G, Zhu W, Smart EJ. Lipids: potential regulators of nitric oxide generation. Am J Physiol Endocrinol Metab 2004; 287: 386–389. http://dx.doi.org/10.1152/ajpendo.00106.2004[Crossref]
• [16] Gong M, Wilson M, Kelly T, et al. HDL-associated estradiol stimulates endothelial NO synthase and vasodilatation in an SR-BI-dependent manner. J Clin Invest 2003;111:1579–1587.
• [17] Zhu X, Bonet B, Gillenwater H, Knopp RH. Opposing effects of estrogen and progestins on LDL oxidation and vascular wall cytotoxicity: implications for atherogenesis. Proc Soc Exp Biol Med 1999; 222: 214–221. http://dx.doi.org/10.1046/j.1525-1373.1999.d01-138.x[Crossref]
• [18] Lobo RA. The role of progestins in hormone replacement therapy. Am J Obstet Gynecol 1992; 166:1997–2004.
• [19] Rosselli M, Imthurn B, Macas E, Keller PJ, Dubey RK. Circulating nitrite/nitrate levels increase with follicular development: indirect evidence for estradiol mediated NO-release. Biochem Biophys Res Commun 1994; 202:1543–1552. http://dx.doi.org/10.1006/bbrc.1994.2107[Crossref]
• [20] Imthurn B, Rosselli M, Jaeger AW, Keller PJ, Dubey RK. Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab 1997; 82: 388–394. http://dx.doi.org/10.1210/jc.82.2.388[Crossref]
• [21] Asagami T, Abbasi F, Stuelinger M, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002;51:843–846. http://dx.doi.org/10.1053/meta.2002.33349[Crossref]
• [22] Wu J, Zhu Y, Jiang Y, Cao Y. Effects of metformin and ethinyl estradiol cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:392–398 http://dx.doi.org/10.1080/09513590802217027[Crossref]
• [23] Mitkov M, Pehlivanov B, Terzieva D. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2006; 126:93–98 http://dx.doi.org/10.1016/j.ejogrb.2005.11.019[Crossref]

Identifiers

DOI

10.2478/s11536-009-0074-x